Review Article

Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis

Takaoki Saneyasu,1 Riaz Akhtar,2 and Takao Sakai1

1MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, UK
2Centre for Materials and Structures, School of Engineering, University of Liverpool, Liverpool L69 3GE, UK

Correspondence should be addressed to Takaao Sakai; sakait@liverpool.ac.uk

Received 10 August 2016; Accepted 28 August 2016

Academic Editor: Yury Popov

Copyright © 2016 Takaoki Saneyasu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tissue and matrix stiffness affect cell properties during morphogenesis, cell growth, differentiation, and migration and are altered in the tissue remodeling following injury and the pathological progression. However, detailed molecular mechanisms underlying alterations of stiffness in vivo are still poorly understood. Recent engineering technologies have developed powerful techniques to characterize the mechanical properties of cell and matrix at nanoscale levels. Extracellular matrix (ECM) influences mechanical tension and activation of pathogenic signaling during the development of chronic fibrotic diseases. In this short review, we will focus on the present knowledge of the mechanisms of how ECM stiffness is regulated during the development of liver fibrosis and the molecules involved in ECM stiffness as a potential therapeutic target for liver fibrosis.

1. Introduction

Each tissue/organ has an optimum stiffness level. The tissue/organ stiffness changes in response to biochemical and physical stimuli during the development or due to pathological conditions such as chronic fibrotic disease and cancer progression [1, 2].

Atomic force microscopy (AFM) allows surface topography of tissues to be imaged with a nanometer spatial resolution using a sharp tip attached to a cantilever. In addition to surface imaging, AFM enables the measurement of mechanical data from tip/sample interaction [3]. AFM is widely used in measuring tissue/organ stiffness at a nanoscale level and cell mechanics. The elastic modulus is typically reported using such AFM data [1, 4]. A number of studies using AFM have assessed tissue/organ stiffness and have revealed that the elastic modulus of soft tissues such as liver, lung, and skin is approximately one-fifth of the level of muscle tissues [1, 4].

Many studies suggest that ECM stiffness affects biological properties of cells and tissues. For example, naive mesenchymal stem cells cultured on soft matrices that mimic brain exhibit neurogenic phenotype, whereas those cultured on stiffer matrices that mimic muscle exhibit myogenic phenotype, suggesting that matrix elasticity governs lineage and phenotypes of stem cells [5]. NIH3T3 fibroblasts on substrates with a rigidity gradient can generate stronger traction forces and spread to a larger size on stiff substrates than on soft substrates [6]. Elevating matrix stiffness increases cell growth and disrupts epithelial morphogenesis by enhancing integrin clustering, extracellular signal-regulated kinase (ERK) activation, and Rho-generated contractility [7]. A recent insightful study shows that collagen cross-linking, which elevates tissue stiffness, leads to cancer progression by enhancing ECM receptor integrin signaling [8]. Therefore, analysis of matrix/tissue stiffness provides us with new insights in understanding the pathological mechanisms of tumor and fibrotic diseases.

Collagen is the most abundant component of scaffolding ECM in tissue/organ stroma [9, 10] and essential for macromolecular structure and organizations in the ECM. Indeed, collagen-mediated ECM networks have an effect on biological properties such as matrix/tissue stiffness and tissue/organ structure. Type I collagen is a member of fibril-forming collagen and the major molecule of collagen fibrils (more than 90%) in bone, tendon, ligament, and skin and...
also all major organs such as heart, kidney, liver, lung, and spleen in vertebrates [10]. Type I collagen is synthesized as procollagen and then forms fibrils after enzyme-mediated removal of both N- and C-terminus propeptides [10]. Cova-

TGF-β plays a pivotal role as a profibrogenic master cytokine in promoting differentiation of tissue-resident fibroblasts into myofibroblasts and upregulation of ECM production, including fibronectin and collagen [15, 16]. TGF-β is secreted into ECM as a biologically inactive (latent) complex with TGF-β latency-associated protein and latent TGF-β-binding protein (LTBP)-1. In response to injury, latent TGF-β is converted to an active form to bind its receptor. Indeed, TGF-β bioavailability is increased in chronic fibrotic diseases, whereas inhibition of latent TGF-β activation prevents the progression of fibrosis [17–20], implying that local activation of latent TGF-β is a critical step in the control of TGF-β activity. Importantly, local TGF-β bioavailability is negatively regulated by fibronectin following adult tissue/organ damage [14, 21].

Liver is responsible for the metabolism, synthesis, storage, and redistribution of nutrients, and it has a central role in homeostasis. Liver injury can be induced by chronic infection with hepatotropic viruses (mainly hepatitis B and C viruses) and autoimmune injury as well as by metabolic and toxic/drug-induced causes, with chronic alcohol consumption being predominant in western countries. Interest-

As described above, collagen cross-linking enhances the ECM stiffness [11]. Accumulating observations have identified molecules regulating protein cross-linking and ECM stiffness (Table 1). The molecules regulating ECM stiffness have relevance to chronic diseases including tissue fibrosis, neurodegenerative, autoimmune disease, and cancer [27, 71].

2.1. Lysyl Oxidase Family. The lysyl oxidase (LOX) family contains at least five members: LOX-like 1 (LOXL1), LOXL2, LOXL3, and LOXL4, in addition to LOX [12, 26]. They belong to an amine oxidase family and copper-dependently catalyze the posttranslational oxidation of peptidyl lysine to the peptidyl aldehyde, α-amino adipic-δ-semialdehyde [12]. This chemical modification is known to be induced by profibrogenic cytokine TGF-β, enables the covalent cross-linking in fibrillar collagens and elastins, and thus results in the insolubilization and stabilization of ECM proteins [8, 72].

LOX is secreted as inactive proenzyme (proLOX) and then extracellularly cleaved to active enzyme by C-proteinase [12, 26]. In vitro study raises the possibility that the proteolytic activation of proLOX occurs on the cell surface in a complex with cellular form of fibronectin [73]. LOX binds to cellular fibronectin at higher binding affinity (Kd = 2.5 nM) as well as type I collagen (Kd = 5.2 nM) and tropoelastin (Kd = 19 nM), although it is unlikely that cellular fibronectin acts as a substrate of LOX. LOX colocalizes well with cellular fibronectin in both cultured fibroblasts in vitro and normal human tissues in vivo. Interestingly, fibronectin-null embryonic fibroblasts...
Table 1: Extracellular matrix stiffness-regulating molecules.

| Molecules                        | Biological functions                                      | References |
|----------------------------------|-----------------------------------------------------------|------------|
| LOX                              | Catalyzing cross-linking of collagen and elastin          | [12, 26]   |
| LOX-like 1–4                     | Catalyzing cross-linking of collagen and elastin          | [12, 26]   |
| Tissue transglutaminase          | Catalyzing cross-linking of ECM proteins                  | [27]       |
| Fibronectin                      | Decreasing LOX family expression                          | [21]       |
| TGF-β                            | Increasing collagen, LOX family expression                | [15, 26]   |
| PDGF                             | Increasing LOX expression                                 | [28, 29]   |
| IL-1β                            | Increasing LOX expression                                 | [30]       |
| TNF-α                            | Decreasing LOX expression (1–5 ng/mL)                     | [31]       |
| Prostaglandin E                  | Decreasing LOX expression                                 | [30]       |
| IFN-γ                            | Decreasing LOX expression                                 | [32]       |

ECM, extracellular matrix; IFN-γ, interferon-γ; IL-1β, interleukin-1β; LOX, lysyl oxidase; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α.

show significant reduction of the proteolytic processing of proLOX [73]. These findings strongly suggest that fibronectin matrix regulates ECM stiffness via LOX activation.

LOX knockout mouse shows perinatal death caused by developmental abnormalities in various tissues such as diaphragm, heart, lung, skin, and vascular tissues [74–76], demonstrating that LOX is essential for normal embryonic development. In both human fibrotic diseases and animal models, elevated expression and activity of LOX family members are often observed [35, 77]. Significantly increased LOX activity is observed in sera of patients with hepatic diseases such as chronic hepatitis, fibrosis, and cirrhosis [78, 79], implying the potential of LOX family as a biomarker for liver fibrosis. LOX inhibitor β-aminopropionitrile (BAPN: small molecule) decreases TGF-β1-induced collagen fibril stiffness in vitro and also organ stiffness following injury [21, 80]. The treatment of BAPN with mice in carbon tetrachloride (CCl4)-induced liver fibrosis facilitates fibrosis reversal after CCl4 withdrawal, supporting the concept of pharmacologic targeting of LOX pathway to inhibit liver fibrosis and promote its resolution [34]. LOXL2-specific inhibitory antibody reduces the extent of collagen cross-linking mediated by pSmad2/3 signaling (canonical TGF-β1 signaling) in mouse models of chemically induced fibrosis in the liver and lung [35] and indeed anti-LOXL2 antibody (GS-6624) in the process of clinical trials [81].

2.2. Transglutaminase Family. The transglutaminase- (TG-) mediated, covalent cross-linking of proteins is an essential step in tissue remodeling after injury. This process provides tissues with extra rigidity and resistance against proteolytic degradation. TGs are widely distributed calcium-dependent enzymes and catalyze covalent cross-linking between γ-carboxy-amine group of a glutamine residue and the ε-amino group of a lysine residue, resulting in a ε-(γ-glutamyl)lysine isopeptide bond [27]. Several studies indicate the involvement of TGs in human diseases such as neurodegenerative disorders, autoimmune diseases, cancer, and tissue/organ fibrosis [27]. The nine members of this family have been identified: TG1 (keratinocyte TG), TG2 (tissue TG), TG3 (epidermal TG), TG4 (prostate TG), TG5 (TGX), TG6 (TGY), TG7 (TGZ), factor XIII, and band 4.2 [82].

TG2 (tissue TG) is the most abundantly expressed member of the TGs [82]. Unlike other members, TG2 is a multifunctional protein and numerous substrates of TG2 have been identified [27, 82]. Many ECM glycoproteins (collagen, fibronectin, fibrinogen, vitronectin, laminin, and LTBP-1) are known to be the substrates of TG2. An in vitro study using Swiss 3T3 fibroblasts suggests the contribution of TG2 to the deposition of latent TGF-β complex into ECM: LTBP-1 is codistributed with extracellular TG2 and fibronectin, and increased TG2 expression elevates the deposition of LTBP-1 in the matrix along with the increase of deoxycholate-insoluble fibronectin, whereas the competitive amine substrate reduces the LTBP-1 deposition in the matrix [83]. Recent studies reveal that TG2 has not only enzymatic (cross-linking of ECM proteins) but also nonenzymatic functions [71]. The cell surface TG2 noncovalently associates with soluble fibronectin and integrin (β1, β3, and β5), resulting in promoting fibronectin deposition into ECM and forming stable ternary complexes with both fibronectin and integrins [71]. The association of TG2 with integrins potentially triggers outside-in signaling. Cell surface TG2 increases RhoA activity by integrin clustering and downregulation of Srcp90RhoGAP inhibitory pathway, enhancing formation of focal adhesion and actin stress fibers [71, 84]. It is therefore likely that TG2 affects ECM/tissue properties via regulating ECM cross-linking and cell-ECM interactions.

Upregulation of TG mRNA and protein levels is observed in human and murine liver fibrosis progression [36, 85]. However, TG2-knockout mice show a comparable extent and pattern of liver fibrosis compared to wild-type controls in CCl4- and thioacetamide-induced chronic liver injury [36]. Furthermore, reversal after CCl4-induced liver fibrosis is not accelerated in TG2-knockout mice. It is therefore likely that TG2 does not have a major contribution to hepatic...
fibrogenesis or stabilization of the collagen matrix and that TG2-independent collagen cross-linking (e.g., LOX family) could be represented as an important therapeutic target for liver fibrosis [36].

Factor XIII (FXIII) plays a central role in forming a stable fibrin meshwork by cross-linking of fibrin during blood clotting [86]. A number of studies have revealed that ECM proteins such as fibronecin, collagen (type I, II, III, and V), and vitronectin are also substrates of FXIII. For example, fibronecin is cross-linked to fibrin α chain by FXIII and this cross-linking produces denser clots [86]. Although fibronecin does not affect clot rigidity at physiological concentrations [86], fibronecin-fibrin cross-linking is required for fibroblast adhesion and spreading on fibronectin. However, the molecular mechanisms underlying impaired wound healing in patients lacking FXIII are still largely unknown [87, 88]. Moreover, the functional requirement for FXIII-mediated cross-linked provisional matrix between fibrin and fibronecin in adult tissue remodeling remains to be defined. We have demonstrated in an FXIII subunit A deficient murine model of acute liver injury that the lack of FXIII subunit A does not interfere with collagen reconstruction and resolution after liver injury. Furthermore, FXIIIA deficiency has caused significantly increased hepatic fibrosis in chronic liver injury induced by CCl\textsubscript{4} where as in single CCl\textsubscript{4} injection causes a similar acute liver injury in knockout and wild-type mice [37]. These findings suggest that ADAMTS2 promotes fibrosis via activation of TGFB\textsubscript{RIII} and that ADAMTS2 might be a novel therapeutic target for liver fibrosis. However, it is unclear whether ADAMTS2 level is elevated in patients with liver fibrosis and whether ADAMTS inhibitors ameliorate fibrosis progression and/or accelerate the regression in animal models. Further studies remain to be elucidated to clarify the contribution of ADAMTS to ECM stiffening and progression/regression of liver fibrosis.

2.4. Small Leucine-Rich Proteoglycans/Protein Family. Small leucine-rich proteoglycans/protein (SLRP) family consists of five classes (I–V) and the canonical class is classes I, II, and, III including decorin, biglycan, lumican, and fibromodulin [91]. Almost all SLRPs bind collagen fibrils through their leucine-rich repeat domain. Lines of evidence show that SLRPs contribute significantly to the diameter and/or alter structure of collagen fibrils [91–93]. A dynamic modulus in biglycan-null tendons is significantly increased compared to wild-type tendons [94]. The elasticity of collagen fiber networks in cultured decorin-siRNA-transfected mouse NIH3T3 fibroblasts declines during the incubation period, whereas it is unchanged in untransfected cells [95]. It is therefore likely that SLRPs could regulate the mechanical strength of ECM.

3. Characterization of Liver Mechanics

In Vitro and In Vivo

The role of mechanical factors in myofibroblastic activation and fibrosis has been recognized for many years [80, 96]. Hence, appropriate techniques are needed to accurately characterize the mechanical changes associated with liver fibrosis. Studies on liver mechanics have been limited due to numerous factors including small sample sizes, variable methodologies, and tissue storage methods. However, it is widely reported that liver is a viscoelastic tissue and that stiffness increases with increasing fibrosis. A range of techniques have been applied to characterize liver mechanics both in vivo and in vitro. For example, magnetic resonance elastography (MRE) has long been used for noninvasive assessment of liver fibrosis [97] and new developments of MRE allow three-dimensional spin-echo planar imaging [98].

For in vitro analysis, oscillatory rheometry which provides the complex shear modulus of liver tissue is typically used for characterization of liver stiffness and data obtained with this technique has been found to correlate with in vivo MRE measurements [99]. Mechanical tissue characterization with rheometry involves the analysis of the complex shear modulus. Very recently, it is shown that the shear storage (\(G'\)), loss (\(G''\)), and apparent Young’s moduli increase markedly with progressive fibrosis in rat livers [100]. They suggest that both cells and the ECM contribute significantly to the mechanical properties of the tissue and that these are driven by cell-cell and cell-ECM contacts. Whilst such approaches provide fundamental mechanical property information on biopsy samples of liver and can be used to develop a constitutive model to understand behavior [100], the information yielded for the samples is at the macroscopic/gross level. Similar to other soft tissues, in the liver, the key components of the ECM, which are altered with fibrosis, are organized at length scales which are not discriminated with conventional mechanical testing techniques [3]. Techniques such as AFM allow the mechanical properties to be probed at the nanoscale and hence open up exciting new areas of research into how the specific components of the tissue microstructure...
influence its mechanical behavior [3]. AFM was originally developed as a topographic imaging technique but is a highly versatile technique where the contrast in AFM images is related to the tip/sample interaction and hence the elastic properties of both tip and substrate [3]. For mechanical property measurements, AFM is typically used in force spectroscopy mode where the mechanical properties of a sample are determined with a high resolution but without correlated surface topography. A recent review by Mave et al. provides an overview of various AFM modes and its use for biomedical applications [101]. The challenges and limitations of AFM-based quantitative mechanical analysis have been reviewed elsewhere [3].

AFM has been used widely to study cell elasticity [102, 103] but to date there are few studies which have determined changes in the properties of native liver tissue with AFM. Recent applications of AFM methods to tissue highlight the utility of such AFM experiments. Zhao et al. [104] used AFM to determine the elastic modulus of biopsy samples obtained from a large cohort of patients in an investigation on the relationship between matrix stiffness and hepatocellular carcinoma. They found a positive correlation between ECM mechanical stiffness and integrin β1 expression, suggesting that integrin β1 expression is regulated by the mechanical stiffness of the ECM. Desai et al. have conducted a detailed AFM study on mice liver lobules from normal and fibrotic livers. They demonstrated that normal liver matrix stiffness was around 150 Pa but increased to 1–6 kPa in areas near fibrillar collagen deposition in fibrotic livers [105]. We have investigated whether ECM glycoprotein fibronectin could be a suitable target for ameliorating fibrosis during advanced stages of chronic liver injury, particularly focusing on the molecular mechanisms responsible for matrix stiffness [21]. We have discovered in liver fibrogenesis induced by CCl4 that fibronectin-null livers have exhibited constitutively elevated local TGF-β activity and lysyl oxidase expressions, induced more myofibroblast phenotypes, accumulated highly disorganized/diffuse collagenous ECM networks, and consequently have led to more extensive liver cirrhosis. Importantly, these phenotypes in fibronectin-null livers are accompanied by significantly elevated liver matrix stiffness, as determined by AFM, and deteriorated hepatic functions. The novel aspect of our AFM experiments is that we have simultaneously imaged the ultrastructure of the tissue and colocated the mechanical properties, using a novel AFM mechanical mapping method [106]. We have found that there is approximately a 55% increase in the elastic modulus of fibronectin-null livers compared to controls in vivo (5.128 ± 553.6 MPa in mutant versus 3.313 ± 835.2 MPa in control; *P < 0.05; measured at ambient conditions) [21]. Further in vitro mechanical integrity analysis reveals that TGF-β1 (2 pM)-induced collagen fibril stiffness in fibronectin-null hepatic myofibroblasts (activated HSCs) is found to be significantly higher compared to control (parental) cells. Furthermore, the treatment of fibronectin-null HSCs with 10 μg/mL plasma fibronectin has recovered collagen fibril stiffness to parental cell levels in vitro [21]. Thus, taken together, these findings indicate that elevated TGF-β bioavailability in fibronectin-null livers induces more active myofibroblasts and sustains their activated phenotypes. As a consequence, these myofibroblasts develop more accumulated collagenous ECMs during advanced chronic liver damage, which thereby results in the significant deterioration of net hepatic function. We propose that there are functional links between fibronectin-mediated control of TGF-β bioavailability and collagen fibril stiffness.

4. Perspectives

Fibrosis is characterized by ECM remodeling and stiffening. Accumulating studies using animal models suggest that the molecules involved in ECM remodeling and stiffening have potential as a therapeutic target for liver fibrosis (Table 2) [107]. Several antifibrotic drugs for fibrosis, including liver fibrosis, are in the process of clinical trials [23, 81, 108]. To date, the therapeutic concept for liver fibrosis has been etiology-driven to ameliorate and eliminate the causative agents of chronic liver disease [81]. More recently, the biochemical changes affecting liver fibrosis irreversibility have become the focus, that is, direct approaches targeting specific ECMs and the extent of matrix stiffness cross-linking. For example, intravenous injection of nanoparticle loaded with procollagen α1(I) siRNA ameliorates progression and accelerates regression of hepatic fibrosis in mice without detectable side effects [44], suggesting that inhibition of de novo collagen synthesis could be a concept in the development of therapeutic agents for chronic hepatic fibrosis. Tissue-resident fibroblasts transdifferentiate into myofibroblasts in response to injury and are responsible for ECM production and remodeling. There are at least two independent mechanisms in type I collagen network organization (fibronectin- and TGF-β/type V collagen-mediated) in response to adult tissue/organ damage [14]. It remains to be elucidated how each mechanism contributes to matrix stiffness during the development of tissue/organ fibrosis. It also remains an unsolved question how ECM stiffness changes during the resolution of liver fibrosis and whether ECM stiffness affects the resolution process. Recent growing evidence has shown that activated HSCs are reverted to quiescent-like state both in vitro [109–113] and in vivo [112, 113], raising the possibility that lowering matrix stiffness initiates the resolution of liver fibrosis. The treatment of LOX inhibitor BAPN decreases collagen stability during liver fibrosis progression and facilitates fibrosis reversal after CCl4-induced advanced liver fibrosis [34]. The monoclonal antibody to LOXL2 has already been in the process of clinical trials [81]. These findings suggest that the decrease of matrix stiffness could also be a treatment strategy for hepatic fibrosis regression.

As described in this review, each of the recent studies suggests that AFM could be a powerful characterization tool to understand mechanistic changes associated with liver disease. Thus, interest in such nanoscale measurements of liver matrix stiffness during the development and progression of liver fibrosis are likely to increase in future work, particularly with the development of new imaging modalities and AFM hardware that improve the quality of data obtained for biological tissues.
| Targets                      | Models                      | Agents to induce injury/fibrosis | Administered drug                  | Effects on injury/fibrosis | References |
|-----------------------------|-----------------------------|---------------------------------|------------------------------------|---------------------------|------------|
| Cross-linking factors       |                             |                                 |                                    |                           |            |
| Factor XIII subunit A       | Knockout mouse              | CCl₄                             |                                    | No effect                 | [33]       |
| LOX                         | Wild-type mouse             | CCl₄                             | Small molecule inhibitor (BAPN)    | Decreasing                | [34]       |
| LOX-like 2                  | Wild-type mouse             | CCl₄                             | Specific antibody                  | Decreasing                | [35]       |
| Tissue transglutaminase     | Knockout mouse              | CCl₄                             |                                    | No effect                 | [36]       |
| Proteases                   |                             |                                 |                                    |                           |            |
| ADAMTS2                     | Knockout mouse              | CCl₄                             |                                    | Decreasing                | [37]       |
| MMP-12                      | Knockout mouse              | CCl₄                             | Bile duct ligation                 | Decreasing                | [38]       |
| MMP-13                      | Knockout mouse              | CCl₄                             | Bile duct ligation                 | Decreasing                | [39]       |
| Osteopontin                 | Knockout mouse              | CCl₄                             |                                    | No effect                 | [40]       |
| Tissue-type plasminogen activator | Knockout mouse | CCl₄                             |                                    | Increasing                | [41]       |
| ECM component               |                             |                                 |                                    |                           |            |
| Fibronectin                 | Wild-type mouse             | CCl₄, DMN                        | Peptide                            | Decreasing                | [42]       |
| Periostin                   | Knockout mouse              | CCl₄                             |                                    | Increasing                | [21]       |
| Procollagen α(I)            | Wild-type mouse             | CCl₄                             | siRNA                              | Decreasing                | [44]       |
| Thrombospondin-1            | Knockout mouse              | CCl₄                             | Resection                          | Decreasing                | [45]       |
| Cytokines/their receptors   |                             |                                 |                                    |                           |            |
| Angiotensin II type 1A receptor | Knockout mouse             | CCl₄                             |                                    | Decreasing                | [46]       |
| Angiotensin II type 2       | Knockout mouse              | CCl₄                             |                                    | Increasing                | [47]       |
| Endothelin-A                | Wild-type rat               | CCl₄                             | Small molecule antagonist (LU135252) | Decreasing                | [48]       |
| TGF-β                       | Wild-type rat               | CCl₄                             | Soluble TGF-β receptor type II     | Decreasing                | [49]       |
| TGF-β type II receptor      | Wild-type rat               | CCl₄                             | BMP-7                              | Decreasing                | [50]       |
| Signal transduction/transcription factors | Knockout mouse | CCl₄                             | BMP-7                              | Decreasing                | [51]       |
| FXR                         | Wild-type rat               | CCl₄                             | Small molecule agonist (6-ECDCA)   | Decreasing                | [52]       |
| JNK1                        | Knockout mouse              | CCl₄                             | Small molecule agonist (6-ECDCA)   | Decreasing                | [53]       |
| MRTF-A                      | Knockout mouse              | CCl₄                             |                                    | Decreasing                | [54]       |
| PPARα                       | Wild-type mouse             | Methionine choline-deficient diet, thioacetamide | Endogenous ligand (oleoylethanolamide) | Decreasing                | [55]       |
| PPARγ                       | Wild-type rat               | CCl₄                             | Small molecule agonist (pioglitazone) | Decreasing                | [56]       |
| Smad3                       | Knockout mouse              | CCl₄                             | Small molecule agonist (pioglitazone) | No effect                 | [57]       |
|                            | Wild-type mouse             | CCl₄                             | Small molecule agonist (pioglitazone) | Increasing                | [58]       |
|                            | Knockout mouse              | CCl₄                             | Thyroid hormone                    | Decreasing                | [59]       |
|                            | Wild-type mouse             | Dimethylnitrosamine              |                                    | Decreasing                | [60]       |
### Table 2: Continued.

| Targets                      | Models                  | Agents to induce injury/fibrosis | Administered drug                              | Effects on injury/fibrosis | References |
|------------------------------|-------------------------|----------------------------------|------------------------------------------------|---------------------------|------------|
| **Others**                   |                         |                                  |                                                |                           |            |
| Cannabinoid receptor CB1     | Wild-type mouse         | CCl₄                              | Small molecule antagonist (SR141716A)           | Decreasing                | [61]       |
|                              | Knockout mouse          | CCl₄, thioacetamide, bile duct ligation |                                              |                           |            |
| Cannabinoid receptor CB2     | Knockout mouse          | CCl₄                              | Small molecule antagonist (EMD527040)           | Increasing                | [62]       |
|                              | Wild-type rat           | Bile duct ligation                | Antibody                                      | Decreasing                | [63]       |
| Integrin αvβ6                | Wild-type mouse         | Bile duct ligation                | Antibody                                      | Decreasing                | [64]       |
|                              | Knockout mouse          | Bile duct ligation                | Antibody                                      | Decreasing                | [64]       |
| Interleukin-I7 receptor      | Knockout mouse          | CCl₄                              | Small molecule inhibitor (GKT137831)            | Decreasing                | [65]       |
| NOX1                         | Wild-type mouse         | CCl₄                              | Small molecule inhibitor (GKT137831)            | Decreasing                | [66]       |
|                              | Knockout mouse          | CCl₄                              | Small molecule inhibitor (GKT137831)            | Decreasing                | [67]       |
| NOX4                         | Wild-type mouse         | CCl₄                              | Small molecule inhibitor (GKT137831)            | Decreasing                | [66]       |
|                              | Knockout mouse          | CCl₄                              | Decreasing                                    |                           | [67]       |

6-ECDCA: 6-α-ethyl-chenodeoxycholic acid; ADAMTS2, A disintegrin and metalloproteinase with thrombospondin type 1 motif 2; BAPN, β-aminopropionitrile; BMP-1, bone morphogenic protein-1; CCl₄, carbon tetrachloride; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DMN, dimethylnitrosamine; FXR, farnesoid X-activated receptor; LOX, lysyl oxidase; MMP, matrix metalloproteinase; MRTF-A, myocardin related transcription factor A; NOX, nicotinamide adenine dinucleotide phosphate oxidase; PPAR, peroxisome proliferator-activated receptor; TGF-β, transforming growth factor-β.

### Abbreviations

- **6-ECDCA**: 6-α-ethyl-chenodeoxycholic acid
- **α-SMA**: α-Smooth muscle actin
- **ADAMTS**: A disintegrin and metalloproteinase with thrombospondin type 1 motif
- **AFM**: Atomic force microscopy
- **BAPN**: β-Aminopropionitrile
- **BMP-1**: Bone morphogenic protein-1
- **CCl₄**: Carbon tetrachloride
- **DDC**: 3,5-Diethoxycarbonyl-1,4-dihydrocollidine
- **DMN**: Dimethylnitrosamine
- **ECM**: Extracellular matrix
- **ERK**: Extracellular signal-regulated kinase
- **FXIII**: Factor XIII
- **FXR**: Farnesoid X-activated receptor
- **HSC**: Hepatic stellate cell
- **IFN-γ**: Interferon-γ
- **IL-1β**: Interleukin-1β
- **LOX**: Lysyl oxidase
- **LOXL**: Lysyl oxidase-like
- **LTBP**: Latent TGF-β-binding protein
- **MRE**: Magnetic resonance elastography
- **MMP**: Matrix metalloproteinase
- **MRTF-A**: Myocardin related transcription factor A
- **NOX**: Nicotinamide adenine dinucleotide phosphate oxidase
- **PPAR**: Peroxisome proliferator-activated receptor
- **PDGF**: Platelet-derived growth factor
- **PI3K**: Phosphoinositide 3-kinase
- **SLRPs**: Small leucine-rich proteoglycans/proteins
- **TGF-β**: Transforming growth factor-β
- **TG**: Transglutaminase
- **TNF**: Tumor necrosis factor

### Competing Interests

The authors disclose no conflict of interests.

### Acknowledgments

The authors wish to acknowledge many outstanding contributions of investigators in the field whose work could not be cited because of space constraints. This work was supported in part by National Institutes of Health research Grant DK074538 (to Takao Sakai). The authors are also grateful to the Institute of Translational Medicine, University of Liverpool, for support (to Takao Sakai).
C. Jimenez Calvente, A. Sehgal, Y. Popov et al., “Specific hepatic K. Kanno, S. Tazuma, and K. Chayama, “AT1A-deficient mice E. Arriazu, X. Ge, T.-M. Leung et al., “Signalling via the osteo- J. J. Cho, B. Hocher, H. Herbst et al., “An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis,” Gastroenterology, vol. 118, no. 6, pp. 1169–1178, 2000. J. George, D. Roulot, V. E. Koteliantsy, and D. M. Bissell, “In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: a potential new therapy for hepatic fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 22, pp. 12719–12724, 1999. S.-L. Wang, C.-Q. Yang, X.-L. Qi et al., “Inhibitory effect of bone morphogenetic protein-7 on hepatic fibrosis in rats,” International Journal of Clinical and Experimental Pathology, vol. 6, no. 5, pp. 897–903, 2013. K. Sakai, S. Jawaid, T. Sasaki, G. Bou-Gharios, and T. Sakai, “Transforming growth Factor-β-Independent role of connective tissue growth factor in the development of liver fibrosis,” American Journal of Pathology, vol. 184, no. 10, pp. 2611–2617, 2014. S. Fiorucci, E. Antonelli, G. Rizzo et al., “The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis,” Gastroenterology, vol. 127, no. 5, pp. 1497–1512, 2004. G. Zhao, M. Hatting, Y. A. Nezvorova et al., “Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis,” Gut, vol. 63, no. 7, pp. 1159–1172, 2014. W. Tian, C. Hao, Z. Fan et al., “Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells,” Journal of Hepatology, vol. 62, no. 1, pp. 165–174, 2015. L. Chen, L. Li, J. Chen et al., “Oleoylthanolamide, an endoge- nous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells,” Oncotarget, vol. 6, no. 40, pp. 42530–42540, 2015. K. Kon, K. Ikejima, M. Hirose et al., “Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachlo- ride,” Biochemical and Biophysical Research Communications, vol. 291, no. 1, pp. 55–61, 2002. A. Da Silva Morais, J. Abarca-Quinones, Y. Horsmans, P. Stärkel, and I. A. Leclercq, “ Peroxisome proliferated-activated receptor γ ligand, pioglitazone, does not prevent hepatic fibrosis in mice,” International Journal of Molecular Medicine, vol. 19, no. 1, pp. 105–112, 2007. E. Morán-Salvador, E. Titos, B. Rius et al., “Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells,” Journal of Hepatology, vol. 59, no. 5, pp. 1045–1053, 2013. E. Alonso-Merino, R. Martín Orozco, L. Ruiz-Llorente et al., “Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 24, pp. E3451–E3460, 2016. G. Latella, A. Vetuschi, R. Sferri et al., “Targeted disruption of Smad3 confers resistance to the development of dimeth- ylnitrosamine-induced hepatic fibrosis in mice,” Liver Interna- tional, vol. 29, no. 7, pp. 997–1009, 2009. F. Teixeira-Clerc, B. Julien, P. Grenard et al., “CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis,” Nature Medicine, vol. 12, no. 6, pp. 671–676, 2006. B. Julien, P. Grenard, F. Teixeira-Clerc et al., “Antifibrogenic role of the cannabinoid receptor CB2 in the liver,” Gastroenterology, vol. 128, no. 3, pp. 742–755, 2005. E. Patsenker, Y. Popov, E. Stickel, A. Jonczyk, S. L. Goodman, and D. Schuppan, “Inhibition of integrin αvβ6 on cholangiocytes blocks transforming growth factor-β activation and retards biliary fibrosis progression,” Gastroenterology, vol. 135, no. 2, pp. 660–670, 2008. B. Wang, B. M. Dolinski, N. Kikuchi et al., “Role of αvβ6 integrin in acute biliary fibrosis,” Hepatology, vol. 46, no. 5, pp. 1404–1412, 2007. Z. Tan, X. Qian, R. Jiang et al., “IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation,” The Journal of Immunology, vol. 191, no. 4, pp. 1835– 1844, 2013. T. Aoyama, Y.-H. Paik, S. Watanabe et al., “Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent,” Hepatology, vol. 56, no. 6, pp. 2316–2327, 2012. T. Lan, T. Kisseleva, and D. A. Brenner, “Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through
inhibition of hepatic stellate cell activation," PLoS ONE, vol. 10, no. 7, Article ID e0129743, 2015.

[68] H. Wang, Y. Zhang, and R. O. Heuckeroth, "PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA," FEBS Letters, vol. 581, no. 16, pp. 3098–3104, 2007.

[69] S. L. Friedman, "Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver," Physiological Reviews, vol. 88, no. 1, pp. 125–172, 2008.

[70] A. L. Olsen, S. A. Bloomer, E. P. Chan et al., "Hepatic stellate cells require a stiff environment for myofibroblastic differentiation," American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 301, no. 1, pp. G110–G118, 2011.

[71] A. M. Belkin, "Extracellular TG2: emerging functions and regulation," The FEBS Journal, vol. 278, no. 24, pp. 4704–4716, 2011.

[72] A. J. van der Slot, E. A. van Dura, E. C. de Wit et al., "Elevated formation of pyridinoline cross-links by probiotic cytokines is associated with enhanced lysyl hydroxylase 2b levels," Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1741, no. 1-2, pp. 92–102, 2005.

[73] B. Fogelgren, N. Polgár, K. M. Szauter et al., "Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation," The Journal of Biological Chemistry, vol. 280, no. 26, pp. 24690–24697, 2005.

[74] J. M. Mäki, R. Sorumnen, S. Lippo, R. Kaarteenaho-Wiik, R. Soininen, and J. Myllyharju, "Lysyl oxidase is essential for the integrity of elastic and collagen fibers in various tissues," American Journal of Pathology, vol. 167, no. 4, pp. 927–936, 2005.

[75] I. K. Hornstrøm, S. Birge, B. Starcher, A. J. Bailey, R. P. Mecham, and S. D. Shapiro, "Lysyl oxidase is required for vascular and diaphragmatic development in mice," The Journal of Biological Chemistry, vol. 278, no. 16, pp. 14387–14393, 2003.

[76] H. E. Barker, T. R. Cox, and J. T. Erler, "The rationale for targeting the LOX family in cancer," Nature Reviews Cancer, vol. 12, no. 8, pp. 540–552, 2012.

[77] O. A. Mesarwi, M.-K. Shin, L. F. Drager et al., "Lysyl oxidase as a serum biomarker of liver fibrosis in patients with severe obesity and obstructive sleep apnea," SLEEP, vol. 38, no. 10, pp. 1583–1591, 2015.

[78] Y. Murawaki, Y. Kusakabe, and C. Hirayama, "Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin," Hepatology, vol. 14, no. 6, pp. 1167–1173, 1991.

[79] P. C. Georges, J.-J. Hui, Z. Gombos et al., "Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis," American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 293, no. 6, pp. G1147–G1154, 2007.

[80] C. Trautwein, S. L. Friedman, D. Schuppan, and M. Pinzani, "Hepatic fibrosis: concept to treatment," Journal of Hepatology, vol. 62, no. 1, pp. S15–S24, 2015.

[81] B. O. Odi and P. Coussons, "Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family," The Scientific World Journal, vol. 2014, Article ID 714561, 13 pages, 2014.

[82] E. Verderio, C. Gaudry, S. Gross, C. Smith, S. Downes, and M. Griffin, "Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor-β binding protein-1," Journal of Histochemistry and Cytochemistry, vol. 47, no. 11, pp. 1417–1432, 1999.

[83] A. Janiai, E. A. Zemskov, and A. M. Belkin, "Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway," Molecular Biology of the Cell, vol. 17, no. 4, pp. 1606–1619, 2006.

[84] P. Grenard, S. Bresson-Hadni, S. El Alaoui, M. Chevallier, D. A. Vuitton, and S. Ricard-Blum, "Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis," Journal of Hepatology, vol. 35, no. 3, pp. 367–375, 2001.

[85] V. R. Richardson, P. Cordell, K. F. Standeven, and A. M. Carter, "Substrates of factor XIII-A: roles in thrombosis and wound healing," Clinical Science, vol. 124, no. 3, pp. 123–137, 2013.

[86] S. E. Ismaa, B. M. Mearns, L. Lorand, and R. M. Graham, "Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders," Physiological Reviews, vol. 89, no. 3, pp. 991–1023, 2009.

[87] A. Inbal, A. Lubetsky, T. Krapp et al., "Impaired wound healing in factor XIII deficient mice," Thrombosis and Haemostasis, vol. 94, no. 2, pp. 432–437, 2005.

[88] R. Kelwick, I. Desanlis, G. N. Wheeler, and D. R. Edwards, "The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family," Genome Biology, vol. 16, article 113, 2015.

[89] M. Bekhouche, C. Leduc, L. Dupont et al., "Determination of the substrate repertoire of ADAMTS2, 3, and 14 significantly broadens their functions and identifies extracellular matrix organization and TGF—signaling as primary targets," The FASEB Journal, vol. 30, no. 5, pp. 1741–1756, 2016.

[90] S. Chen and D. E. Birk, "The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly," FEBS Journal, vol. 280, no. 10, pp. 2120–2137, 2013.

[91] S. Kalamajska and A. Oldberg, "The role of small leucine-rich proteoglycans in collagen fibrillogenesis," Matrix Biology, vol. 29, no. 4, pp. 248–253, 2010.

[92] D. Heinégärd, "Proteoglycans and more—from molecules to biology," International Journal of Experimental Pathology, vol. 90, no. 6, pp. 575–586, 2009.

[93] L. M. Dourte, L. Pathmanathan, M. J. Mienaltowski, A. F. Jawad, D. E. Birk, and L. J. Slosowsky, "Mechanical, compositional, and structural properties of the mouse patellar tendon with changes in biglycan gene expression," Journal of Orthopaedic Research, vol. 31, no. 9, pp. 1430–1437, 2013.

[94] S. Iwasaki, Y. Hosaka, T. Iwasaki et al., "The modulation of collagen fibril assembly and its structure by decorin: an electron microscopic study," Archives of Histology and Cytology, vol. 71, no. 1, pp. 37–44, 2008.

[95] B. Hinz, S. H. Phan, V. J. Thannickal et al., "Recent developments in myofibroblast biology: paradigms for connective tissue remodeling," The American Journal of Pathology, vol. 180, no. 4, pp. 1340–1355, 2012.

[96] L. Huwart, C. Sempoux, E. Vicaut et al.,” Impaired wound healing in biglycan gene expression,” Archives of Pathology and Laboratory Medicine, vol. 124, no. 3, pp. 123–137, 2010.

[97] S. Chen and D. E. Birk, "The regulatory roles of small leucine-rich proteoglycans in collagen fibrillogenesis," Matrix Biology, vol. 29, no. 4, pp. 248–253, 2010.

[98] S. Iwasaki, Y. Hosaka, T. Iwasaki et al., "The modulation of collagen fibril assembly and its structure by decorin: an electron microscopic study," Archives of Histology and Cytology, vol. 71, no. 1, pp. 37–44, 2008.

[99] B. Hinz, S. H. Phan, V. J. Thannickal et al., "Recent developments in myofibroblast biology: paradigms for connective tissue remodeling," The American Journal of Pathology, vol. 180, no. 4, pp. 1340–1355, 2012.
planar imaging: a prospective study,” *The American Journal of Gastroenterology*, vol. 111, no. 6, pp. 823–833, 2016.

[99] D. Klatt, C. Friedrich, Y. Korth, R. Vogt, J. Braun, and I. Sack, “Viscoelastic properties of liver measured by oscillatory rheometry and multifrequency magnetic resonance elastography,” *Biorheology*, vol. 47, no. 2, pp. 133–141, 2010.

[100] M. Perepelyuk, L. Chin, X. Cao et al., “Normal and fibrotic rat livers demonstrate shear strain softening and compression stiffening: a model for soft tissue mechanics,” *PLoS ONE*, vol. 11, no. 1, Article ID e0146588, 2016.

[101] U. Maver, T. Velnar, M. Gaberšček, O. Planinšek, and M. Finšgar, “Recent progressive use of atomic force microscopy in biomedical applications,” *TrAC—Trends in Analytical Chemistry*, vol. 80, pp. 96–111, 2016.

[102] C. Rotsch, F. Braet, E. Wisse, and M. Radmacher, “AFM imaging and elasticity measurements on living rat liver macrophages,” *Cell Biology International*, vol. 21, no. 11, pp. 685–696, 1997.

[103] T. G. Kuznetsova, M. N. Starodubtseva, N. I. Yegorenkov, S. A. Chizhik, and R. I. Zhdanov, “Atomic force microscopy probing of cell elasticity,” *Micron*, vol. 38, no. 8, pp. 824–833, 2007.

[104] G. Zhao, J. Cui, Q. Qin et al., “Mechanical stiffness of liver tissues in relation to integrin $\beta_1$ expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma,” *Journal of Surgical Oncology*, vol. 102, no. 5, pp. 482–489, 2010.

[105] S. S. Desai, J. C. Tung, V. X. Zhou et al., “Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha,” *Hepatology*, vol. 64, no. 1, pp. 261–275, 2016.

[106] M. Papi, P. Paoletti, B. Geragthy, and R. Akhtar, “Nanoscale characterization of the biomechanical properties of collagen fibrils in the sclera,” *Applied Physics Letters*, vol. 104, Article ID 103703, 2014.

[107] H. Hayashi and T. Sakai, “Animal models for the study of liver Fibrosis: new insights from knockout mouse models,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 300, no. 5, pp. G729–G738, 2011.

[108] T. A. Wynn and T. R. Ramalingam, “Mechanisms of fibrosis: therapeutic translation for fibrotic disease,” *Nature Medicine*, vol. 18, no. 7, pp. 1028–1040, 2012.

[109] S. Hazra, S. Xiong, J. Wang, R. A. Rippe, V. K. K. Chatterjee, and H. Tsukamoto, “Peroxisome proliferator-activated receptor y induces a phenotypic switch from activated to quiescent hepatic stellate cells,” *The Journal of Biological Chemistry*, vol. 279, no. 12, pp. 11392–11401, 2004.

[110] H. She, S. Xiong, S. Hazra, and H. Tsukamoto, “Adipogenic transcriptional regulation of hepatic stellate cells,” *The Journal of Biological Chemistry*, vol. 280, no. 6, pp. 4959–4967, 2005.

[111] A. El Taghdouini, M. Najimi, P. Sancho-Bru, E. Sokal, and L. A. van Grunsven, “In vitro reversion of activated primary human hepatic stellate cells,” *Fibrogenesis & Tissue Repair*, vol. 8, article 14, 2015.

[112] T. Kisseleva, M. Cong, Y. Paik et al., “Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 24, pp. 9448–9453, 2012.

[113] J. S. Troeger, I. Mederacke, G.-Y. Gwak et al., “Deactivation of hepatic stellate cells during liver fibrosis resolution in mice,” *Gastroenterology*, vol. 143, no. 4, pp. 1073–1083.e22, 2012.